Nem metastaticus rectumtumorok egyedüli preoperatív besugárzásával szerzett tapasztalataink = Experiences on non-metastatic rectum tumours irradiated only preoperatively

Elfogadott ténynek számít, hogy a nem metastaticus rectumtumorok egyedüli preoperatív sugárterápiájával a lokálrecidíva-ráta 50%-kal csökkenthető. Beteganyag és módszer: 1990 és 2001 között 181 rectumtumoros betegnél végeztünk preoperatív célú 36 Gy, illetve 40 Gy dózisú irradiációt. A stádiumba sorolást a módosított Astler–Coller patológiai staging szisztéma szerint végeztük. A sugárkezelést telekobalt-készülékkel, illetve nagyenergiájú fotonbesugárzóval végeztük számítógépes besugárzástervezést követően. Eredmény: A preoperatív sugárkezelés eredményességének legfontosabb fokmérője a lokálrecidíva-ráta, mely anyagunkban 21,56%-os volt. Szignifikánsan befolyásolta a túlélést a beteg kora és az alkalmazott dózis nagysága. Következtetés: Rectumtumoros beteganyagunk statisztikai analízise az egyedüli preoperatív sugárkezelés hatékonyságát vizsgálta. Az eredmények megfeleltek az erre vonatkozó közleményekben közöltekkel. | Introduction: It is an accepted fact that the local recurrence rate can be decreased up to 50% for the metastatic rectum tumours irradiated only preoperatively. Materials and methods: 181 patients having rectum tumour were irradiated preoperatively with 36 or 40 Gy between 1990 and 2001. The classification was made according to the modified Astler–Coller pathological staging system. The radiation treatment was carried out with telecobalt unit or high energy photon of linear accelerator after computerized radiation treatment planning. Results: The most important characterizing factor for the efficiency of the preoperative irradiation is the local recurrence rate that was found to be 21.56% in our investigation. The survival rate was significantly influenced by the age of the patient and the applied dose. Conclusion: Our statistical analysis was applied to investigate the efficiency of the only preoperatively irradiated patients. The results are in agreement with the reported contributions

Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study

Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data are still limited. Here, we aimed to evaluate the efficacy and the safety of cemiplimab in a real-world clinical setting. Methods: A retrospective analysis was carried out for all patients who received at least two doses of cemiplimab at our department between February 2020 and January 2023. Progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the disease control rate (DCR) and adverse events (AEs) were evaluated. Results: Twenty-five patients were included with a median age of 78 (65–82) years. The median treatment duration was 48 (16–72) weeks. Five (20%) patients were immunocompromised. Sixteen patients (64%) developed AEs, including 36% serious AEs (SAEs) of grade ≥ 3. Six patients (24%) were withdrawn from treatment due to the occurrence of AEs. Among the 25 patients, 52% showed an objective response (3 complete and 10 partial responses), 76% had controlled disease and 24% experienced progression. Among the five immunocompromised patients, the ORR was 60%, while the DCR was 80%. Conclusions: This retrospective real-world study revealed that locally advanced or metastatic cSCC could be effectively treated with cemiplimab even in elderly, polymorbid and immunocompromised patients